Gilead Sciences

CompanyMentioned in 1 video

The pharmaceutical company that acquired Kite Pharma for $11.9 billion in 2017, making anti-CD19 CAR T-cell therapy widely available.

Videos Mentioning Gilead Sciences

177 - The development of cancer immunotherapy and its promise for treating advanced cancers

177 - The development of cancer immunotherapy and its promise for treating advanced cancers

Peter Attia MD

The pharmaceutical company that acquired Kite Pharma for $11.9 billion in 2017, making anti-CD19 CAR T-cell therapy widely available.